A Primer on Gout: Flares, Fixes, and the Future

Research evidence excerpt

A Primer on Gout: Flares, Fixes, and the Future

Quick Note

July 6, 2026 Biotechnology

Analysts

Robert Driscoll, Ph.D.

(415) 274-6863 Gout is the most prevalent inflammatory arthritis, and is characterized by acuteRobert.Driscoll@wedbush.com

intermittent episodes of joint swelling and severe pain (flares) that can increaseGeoffrey Von Der Ahe

(628) 223-0517 in frequency and severity over time. Advanced disease develops in approximately

geoffrey.vonderahe@wedbush.com 15% of patients and is characterized by the development of subcutaneous

nodules composed of monosodium urate (tophi), which result in inflammation and

potential joint erosion and deformity.

Hyperuricemia is a necessary risk factor for gout, and occurs due to the

overproduction or most commnly underexcretion of uric acid. In addition to

endogenous production and underexcretion, consumption of purine-rich foods,

including alcohol, red meat and seafood, can also promote hyperuricemia.

However, dietary modifications in patients typically result in only modest

reductions in serum urate, and suffer from low rates of compliance. Therapies

used to manage acute gout flares and urate lowering therapies (ULTs) have

contraindications with comorbidities, and gout disproportionately affects older

adults, who frequently have comorbid conditions such as chronic kidney disease

and cardiovascular disease. A subset of patients fails to achieve serum urate target

goals owing to intolerance or inadequate response to available agents.

Here, we provide an overview of gout, the current and emerging treatment

landscape, and highlight companies working in the space. These include

Monte Rosa Therapeutics (GLUE, OUTPERFORM) developing Nek7 molecular glue

degrader MRT-8102 for the treatment of acute gout flares and potentially anti-